Clinical trial
Preoperative Radiotherapy/ Oxaliplatin/ Capecitabine Treatment For Unresectable…
NCT00263029 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00263029 |
|---|---|
| Title | Preoperative Radiotherapy/ Oxaliplatin/ Capecitabine Treatment For Unresectable Locally-advanced Rectal Cancer |
| Official title | Pre-operative Radiotherapy/ Oxaliplatin/ Capecitabine Treatment For Unresectable Locally-advanced Rectal Cancer (PROCTFUL) |
| Acronym | PROCTFUL |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rectal Neoplasms |
| Intervention type | Drug, Radiation |
| Interventions | Oxaliplatin, Capecitabine, Radiotherapy |
| Enrollment | 18 |
| Start date | Jun 1, 2002 |
| Primary completion | Mar 1, 2007 |
| First posted | Dec 7, 2005 |
| Last update posted | Sep 18, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: